|
Patent landscape, scope, and claims: |
Overview of Patent 9,585,838
Patent 9,585,838 was granted to Takeda Pharmaceutical Company Limited on February 28, 2017. It pertains to a novel class of compounds used as inhibitors of Bruton’s tyrosine kinase (BTK), emphasizing therapeutic potential in immune-related disorders and certain cancers.
Scope and Claims Analysis
Claims Breakdown
The patent's claims broadly encompass:
- Claim 1: A compound of formula (I), defined by specific chemical structures and substituents, where R1, R2, R3, R4, and R5 denote particular groups, with variations explicitly described.
- Claims 2-10: Dependent claims elaborating on specific substituents, stereochemistry, and embodiments within the broad compound class claimed in Claim 1.
- Claims 11-20: Covering pharmaceutical compositions comprising the compounds, methods of treating diseases involving BTK inhibition, and methods of preparation.
Key Claim Characteristics
- The core chemical structure is a substituted pyrimidine or purine derivative.
- The claims specify substitution patterns on the heterocyclic core, focusing on bulky or specific functional groups to enhance activity and selectivity.
- The patent emphasizes compounds with high potency against BTK, optimized pharmacokinetic profiles, and selectivity over kinase family members like ITK or TEC.
Claim Scope Limitations
- The patent primarily claims compounds with specific substitutions, not all possible BTK inhibitors.
- It emphasizes use in autoimmune diseases (e.g., rheumatoid arthritis, lupus) and B-cell malignancies, with permissible variations in formulations and methods.
- The patent does not claim methods of synthesis in broad terms, focusing instead on compound structures and pharmaceutical compositions.
Patent Landscape
Related Patents
- Multiple patents exist describing BTK inhibitors, notably from other pharmaceutical entities like AbbVie, AstraZeneca, and Janssen.
- Takeda’s patent covers derivatives with key structural differences, such as specific heteroatoms and substitution patterns, setting it apart in the patent space.
Key Competitors & Patent Families
| Patent Number |
Holder |
Focus |
Jurisdiction |
Priority Date |
| US 9,585,838 |
Takeda |
BTK inhibitors with specific substitutions |
US, WO (worldwide) |
2014-05-30 |
| US 9,568,872 |
AbbVie |
Covalently bound BTK inhibitors |
US, EP |
2014-03-25 |
| EP 2,800,102 |
AstraZeneca |
Pyrimidine-based kinase inhibitors |
Europe |
2014-07-15 |
| US 10,011,484 |
Janssen |
Selective BTK inhibitors |
US, WIPO |
2016-08-02 |
Legal Status
- The patent is enforceable until 2034, considering a 20-year term from the earliest priority date.
- It remains in force in US markets, asserting exclusivity over the claimed chemical class.
Patent Challenges and Limitations
- Any prior art that discloses similar heterocyclic compounds with BTK activity could pose a challenge.
- The specificity of claims to particular substitution patterns limits the scope but also creates clear boundaries for patent infringement.
Emerging Trends in Patent Filings
- Recent filings extend into covalent inhibitors and irreversible binders.
- Strategies focus on enhancing selectivity among kinases to reduce off-target effects.
- Patent families increasingly include formulations with fixed-dose combinations and novel delivery methods.
Implications for R&D and Competition
The patent landscape confirms Takeda’s strategic protection over specific BTK inhibitors. The narrow claim scope provides room for competitor innovation but also delineates the boundaries of Takeda’s exclusive rights.
Companies exploring BTK inhibition should analyze corresponding patents for claims on structural features, methods of synthesis, and therapeutic claims to avoid infringement. Patent litigation may arise if competitors develop compounds with similar substitution patterns or use proposed chemical frameworks.
Key Takeaways
- Patent 9,585,838 claims specific substituted heterocyclic compounds as BTK inhibitors, primarily for autoimmune and hematologic indications.
- It covers a broad chemical class with specific substitution patterns, making it a strong exclusivity claim over similar compounds.
- The patent landscape is crowded but differentiated; competitors focus on covalent binding, selectivity, and alternative chemical scaffolds.
- Enforcement is expected until 2034, with ongoing patent applications expanding claims in related kinase inhibitor spaces.
- Strategic patent filings by competitors indicate a highly active R&D environment in selective BTK inhibition.
FAQs
-
What is the primary therapeutic focus of Patent 9,585,838?
It targets BTK inhibitors for autoimmune diseases and B-cell malignancies.
-
Does the patent cover covalent or irreversible inhibitors?
No, it primarily covers reversible heterocyclic compounds with specific substitution patterns.
-
What is the competitive landscape for BTK patents?
Multiple firms, including AbbVie, AstraZeneca, and Janssen, hold patents on structurally distinct BTK inhibitors, often focusing on covalent binding and selectivity.
-
Are there known patent challenges to Takeda’s patent?
While no publicly documented litigations, prior arts in kinases with similar structures exist, which could be considered during validity disputes.
-
What are the patent expiry prospects?
The patent is set to expire in 2034, giving Takeda market exclusivity through that period.
References
- U.S. Patent 9,585,838.
- Patent landscape reports, biopharma patent databases.
- World Intellectual Property Organization (WIPO), Patentscope.
- PTAB challenges and patent litigation records (public filings).
More… ↓
⤷ Start Trial
|
